Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pasireotide Treatment for Neuroendocrine Tumor
NCT02779257 · University of Maryland, Baltimore · PHASE4 · withdrawn · last registry update 2022-03-04 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Subject passed away prior to enrollment” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SSTR5 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-02-21Also stopped (withdrawn): British Columbia Cancer Agency, 177Lu-DOTATOC (NCT04915144)
- 2023-01-18Also stopped (terminated): Federation Francophone de Cancerologie Digestive, lanreotide + Placebo (NCT02288377)
- 2022-09-28Results posted on the registry: Duke University, Lanreotide + Pembrolizumab (NCT03043664)
- 2022-07-28Phase 3 first posted: RayzeBio, Inc., RYZ101 + Everolimus (NCT05477576)
- 2022-06-16Results posted on the registry: University of Washington, Lanreotide Prefilled Syringe (NCT03174353)
- 2021-10-04Results posted on the registry: Federation Francophone de Cancerologie Digestive, lanreotide + Placebo (NCT02288377)
- 2021-09-21Phase 3 first posted: Camurus AB, CAM2029 + Octreotide LAR (NCT05050942)
- 2021-04-21Phase 3 first posted: Ipsen, Lanreotide autogel (NCT04852679)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision